

David Nemazee

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/4678982/david-nemazee-publications-by-year.pdf>

Version: 2024-04-27

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

125
papers

8,868
citations

45
h-index

93
g-index

139
ext. papers

10,855
ext. citations

16.6
avg, IF

6.22
L-index

#	Paper	IF	Citations
125	A pandemic-enabled comparison of discovery platforms demonstrates a naïve antibody library can match the best immune-sourced antibodies.. <i>Nature Communications</i> , 2022 , 13, 462	17.4	3
124	A human antibody reveals a conserved site on beta-coronavirus spike proteins and confers protection against SARS-CoV-2 infection.. <i>Science Translational Medicine</i> , 2022 , 14, eabi9215	17.5	15
123	Broadly neutralizing anti-S2 antibodies protect against all three human betacoronaviruses that cause severe disease. 2022 ,		2
122	A broad and potent neutralization epitope in SARS-related coronaviruses. 2022 ,		2
121	Broadly neutralizing antibodies target the coronavirus fusion peptide. 2022 ,		3
120	Cleavage of DNA and RNA by PLD3 and PLD4 limits autoinflammatory triggering by multiple sensors. <i>Nature Communications</i> , 2021 , 12, 5874	17.4	2
119	A protective broadly cross-reactive human antibody defines a conserved site of vulnerability on beta-coronavirus spikes 2021 ,		26
118	SARS-CoV-2 Serology Status Detected by Commercialized Platforms Distinguishes Previous Infection and Vaccination Adaptive Immune Responses 2021 ,		3
117	Ultrapotent bispecific antibodies neutralize emerging SARS-CoV-2 variants 2021 ,		6
116	Cross-reactive serum and memory B-cell responses to spike protein in SARS-CoV-2 and endemic coronavirus infection. <i>Nature Communications</i> , 2021 , 12, 2938	17.4	110
115	Structural and functional ramifications of antigenic drift in recent SARS-CoV-2 variants. <i>Science</i> , 2021 , 373, 818-823	33.3	148
114	A combination of cross-neutralizing antibodies synergizes to prevent SARS-CoV-2 and SARS-CoV pseudovirus infection. <i>Cell Host and Microbe</i> , 2021 , 29, 806-818.e6	23.4	24
113	Commercial Serology Assays Predict Neutralization Activity against SARS-CoV-2. <i>Clinical Chemistry</i> , 2021 , 67, 404-414	5.5	32
112	Structural and functional ramifications of antigenic drift in recent SARS-CoV-2 variants 2021 ,		26
111	Broad and potent activity against SARS-like viruses by an engineered human monoclonal antibody. <i>Science</i> , 2021 , 371, 823-829	33.3	157
110	A combination of cross-neutralizing antibodies synergizes to prevent SARS-CoV-2 and SARS-CoV pseudovirus infection 2021 ,		3
109	Natural history of MZ B cells. <i>Journal of Experimental Medicine</i> , 2021 , 218,	16.6	4

108	SARS-CoV-2 Serology Status Detected by Commercialized Platforms Distinguishes Previous Infection and Vaccination Adaptive Immune Responses. <i>Journal of Applied Laboratory Medicine, The</i> , 2021 , 6, 1109-1122	2	10
107	Bispecific antibodies targeting distinct regions of the spike protein potentially neutralize SARS-CoV-2 variants of concern. <i>Science Translational Medicine</i> , 2021 , 13, eabj5413	17.5	18
106	B Cells Carrying Antigen Receptors Against Microbes as Tools for Vaccine Discovery and Design. <i>Current Topics in Microbiology and Immunology</i> , 2020 , 428, 165-180	3.3	
105	MicroRNA control of B cell tolerance, autoimmunity and cancer. <i>Seminars in Cancer Biology</i> , 2020 , 64, 102-107	12.7	12
104	Isolation of potent SARS-CoV-2 neutralizing antibodies and protection from disease in a small animal model. <i>Science</i> , 2020 , 369, 956-963	33.3	906
103	Broad neutralization of SARS-related viruses by human monoclonal antibodies. <i>Science</i> , 2020 , 369, 731-736	33.3	376
102	Prediabetes Induced by a Single Autoimmune B Cell Clone. <i>Frontiers in Immunology</i> , 2020 , 11, 1073	8.4	0
101	A natural mutation between SARS-CoV-2 and SARS-CoV determines neutralization by a cross-reactive antibody. <i>PLoS Pathogens</i> , 2020 , 16, e1009089	7.6	33
100	Rapid isolation of potent SARS-CoV-2 neutralizing antibodies and protection in a small animal model 2020 ,		35
99	Broad sarbecovirus neutralizing antibodies define a key site of vulnerability on the SARS-CoV-2 spike protein 2020 ,		18
98	Structural analysis of full-length SARS-CoV-2 spike protein from an advanced vaccine candidate 2020 ,		8
97	A natural mutation between SARS-CoV-2 and SARS-CoV determines neutralization by a cross-reactive antibody 2020 ,		2
96	Cross-reactive serum and memory B cell responses to spike protein in SARS-CoV-2 and endemic coronavirus infection 2020 ,		40
95	An Engineered Antibody with Broad Protective Efficacy in Murine Models of SARS and COVID-19 2020 ,		11
94	Structural analysis of full-length SARS-CoV-2 spike protein from an advanced vaccine candidate. <i>Science</i> , 2020 , 370, 1089-1094	33.3	153
93	Vaccine elicitation of HIV broadly neutralizing antibodies from engineered B cells. <i>Nature Communications</i> , 2020 , 11, 5850	17.4	17
92	Structural and functional evaluation of de novo-designed, two-component nanoparticle carriers for HIV Env trimer immunogens. <i>PLoS Pathogens</i> , 2020 , 16, e1008665	7.6	25
91	B cells expressing authentic naive human VRC01-class BCRs can be recruited to germinal centers and affinity mature in multiple independent mouse models. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2020 , 117, 22920-22931	11.5	20

90	Induction of Cross-Reactive and Protective Antibody Responses After DNA Vaccination With MHCII-Targeted Stem Domain From Influenza Hemagglutinin. <i>Frontiers in Immunology</i> , 2020 , 11, 431	8.4	1
89	Structural and functional evaluation of de novo-designed, two-component nanoparticle carriers for HIV Env trimer immunogens 2020 , 16, e1008665		
88	Structural and functional evaluation of de novo-designed, two-component nanoparticle carriers for HIV Env trimer immunogens 2020 , 16, e1008665		
87	Structural and functional evaluation of de novo-designed, two-component nanoparticle carriers for HIV Env trimer immunogens 2020 , 16, e1008665		
86	Structural and functional evaluation of de novo-designed, two-component nanoparticle carriers for HIV Env trimer immunogens 2020 , 16, e1008665		
85	Immunogenicity of RNA Replicons Encoding HIV Env Immunogens Designed for Self-Assembly into Nanoparticles. <i>Molecular Therapy</i> , 2019 , 27, 2080-2090	11.7	27
84	Detection and activation of HIV broadly neutralizing antibody precursor B cells using anti-idiotypes. <i>Journal of Experimental Medicine</i> , 2019 , 216, 2331-2347	16.6	9
83	Activated protein C ameliorates chronic graft-versus-host disease by PAR1-dependent biased cell signaling on T cells. <i>Blood</i> , 2019 , 134, 776-781	2.2	6
82	Reprogramming the antigen specificity of B cells using genome-editing technologies. <i>ELife</i> , 2019 , 8,	8.9	30
81	Precursor Frequency and Affinity Determine B Cell Competitive Fitness in Germinal Centers, Tested with Germline-Targeting HIV Vaccine Immunogens. <i>Immunity</i> , 2018 , 48, 133-146.e6	32.3	173
80	Generation of T follicular helper cells in vitro: requirement for B-cell receptor cross-linking and cognate B- and T-cell interaction. <i>Immunology</i> , 2018 , 153, 214-224	7.8	14
79	PLD3 and PLD4 are single-stranded acid exonucleases that regulate endosomal nucleic-acid sensing. <i>Nature Immunology</i> , 2018 , 19, 942-953	19.1	56
78	HIV-1 vaccine design through minimizing envelope metastability. <i>Science Advances</i> , 2018 , 4, eaau6769	14.3	43
77	PLD3 and spinocerebellar ataxia. <i>Brain</i> , 2018 , 141, e78	11.2	7
76	The Bacterial Peptidoglycan-Sensing Molecules NOD1 and NOD2 Promote CD8 Thymocyte Selection. <i>Journal of Immunology</i> , 2017 , 198, 2649-2660	5.3	14
75	Mechanisms of central tolerance for B cells. <i>Nature Reviews Immunology</i> , 2017 , 17, 281-294	36.5	183
74	Design and crystal structure of a native-like HIV-1 envelope trimer that engages multiple broadly neutralizing antibody precursors in vivo. <i>Journal of Experimental Medicine</i> , 2017 , 214, 2573-2590	16.6	100
73	Regulation of B-cell development and tolerance by different members of the miR-17~92 family microRNAs. <i>Nature Communications</i> , 2016 , 7, 12207	17.4	50

72	The microRNA miR-148a functions as a critical regulator of B cell tolerance and autoimmunity. <i>Nature Immunology</i> , 2016 , 17, 433-40	19.1	88
71	Receptor editing and genetic variability in human autoreactive B cells. <i>Journal of Experimental Medicine</i> , 2016 , 213, 93-108	16.6	28
70	Central B Cell Tolerance 2016 , 78-82		
69	Presenting native-like trimeric HIV-1 antigens with self-assembling nanoparticles. <i>Nature Communications</i> , 2016 , 7, 12041	17.4	101
68	Tailored Immunogens Direct Affinity Maturation toward HIV Neutralizing Antibodies. <i>Cell</i> , 2016 , 166, 1459-1470.e11	56.2	178
67	High-Density Array of Well-Ordered HIV-1 Spikes on Synthetic Liposomal Nanoparticles Efficiently Activate B Cells. <i>Cell Reports</i> , 2016 , 15, 1986-99	10.6	89
66	HIV-1 VACCINES. Priming a broadly neutralizing antibody response to HIV-1 using a germline-targeting immunogen. <i>Science</i> , 2015 , 349, 156-61	33.3	264
65	Rational HIV immunogen design to target specific germline B cell receptors. <i>Science</i> , 2013 , 340, 711-6	33.3	519
64	2G12-expressing B cell lines may aid in HIV carbohydrate vaccine design strategies. <i>Journal of Virology</i> , 2013 , 87, 2234-41	6.6	18
63	Immune tolerance negatively regulates B cells in knock-in mice expressing broadly neutralizing HIV antibody 4E10. <i>Journal of Immunology</i> , 2013 , 191, 3186-3191	5.3	81
62	B cells from knock-in mice expressing broadly neutralizing HIV antibody b12 carry an innocuous B cell receptor responsive to HIV vaccine candidates. <i>Journal of Immunology</i> , 2013 , 191, 3179-85	5.3	31
61	Skewed primary Ig λ repertoire and V-J joining in C57BL/6 mice: implications for recombination accessibility and receptor editing. <i>Journal of Immunology</i> , 2012 , 188, 2305-15	5.3	44
60	Anti-HIV B Cell lines as candidate vaccine biosensors. <i>Journal of Immunology</i> , 2012 , 189, 4816-24	5.3	48
59	The P4-type ATPase ATP11C is essential for B lymphopoiesis in adult bone marrow. <i>Nature Immunology</i> , 2011 , 12, 434-40	19.1	73
58	Liver-expressed Igkappa superantigen induces tolerance of polyclonal B cells by clonal deletion not kappa to lambda receptor editing. <i>Journal of Experimental Medicine</i> , 2011 , 208, 617-29	16.6	16
57	Negative selection by IgM superantigen defines a B cell central tolerance compartment and reveals mutations allowing escape. <i>Journal of Immunology</i> , 2011 , 187, 5596-605	5.3	21
56	Decoration of T-independent antigen with ligands for CD22 and Siglec-G can suppress immunity and induce B cell tolerance in vivo. <i>Journal of Experimental Medicine</i> , 2010 , 207, 173-87	16.6	120
55	A mutation of Ikbkg causes immune deficiency without impairing degradation of IkappaB alpha. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2010 , 107, 3046-51	11.5	20

54	Regulation of the B cell receptor repertoire and self-reactivity by BAFF. <i>Journal of Immunology</i> , 2010 , 185, 4128-36	5.3	74
53	Peripheral B cell tolerance and function in transgenic mice expressing an IgD superantigen. <i>Journal of Immunology</i> , 2010 , 184, 4143-58	5.3	16
52	Deletion of IgG-switched autoreactive B cells and defects in Fas(lpr) lupus mice. <i>Journal of Immunology</i> , 2010 , 185, 1015-27	5.3	22
51	Suppression of IgE B cells and IgE binding to Fc(epsilon)RI by gene therapy with single-chain anti-IgE. <i>Journal of Immunology</i> , 2009 , 182, 8110-7	5.3	15
50	Distinct roles for E12 and E47 in B cell specification and the sequential rearrangement of immunoglobulin light chain loci. <i>Journal of Experimental Medicine</i> , 2009 , 206, 2271-84	16.6	64
49	Rearrangement of mouse immunoglobulin kappa deleting element recombining sequence promotes immune tolerance and lambda B cell production. <i>Immunity</i> , 2008 , 28, 161-70	32.3	40
48	FGD2, a CDC42-specific exchange factor expressed by antigen-presenting cells, localizes to early endosomes and active membrane ruffles. <i>Journal of Biological Chemistry</i> , 2008 , 283, 34002-12	5.4	39
47	Basal B cell receptor-directed phosphatidylinositol 3-kinase signaling turns off RAGs and promotes B cell-positive selection. <i>Journal of Immunology</i> , 2007 , 178, 6332-41	5.3	81
46	Reduced receptor editing in lupus-prone MRL/lpr mice. <i>Journal of Experimental Medicine</i> , 2007 , 204, 2853-64	36.4	34
45	Polyspecificity of T cell and B cell receptor recognition. <i>Seminars in Immunology</i> , 2007 , 19, 216-24	10.7	159
44	Role of RS/kappaDE in B cell receptor editing. <i>Advances in Experimental Medicine and Biology</i> , 2007 , 596, 169-72	3.6	1
43	Effect of cell:cell competition and BAFF expression on peripheral B cell tolerance and B-1 cell survival in transgenic mice expressing a low level of Igkappa-reactive macroself antigen. <i>European Journal of Immunology</i> , 2006 , 36, 985-96	6.1	15
42	Paucity of V-D-D-J rearrangements and VH replacement events in lupus prone and nonautoimmune TdT ^{-/-} and TdT ^{+/+} mice. <i>Journal of Immunology</i> , 2006 , 177, 1120-8	5.3	24
41	Split tolerance in peripheral B cell subsets in mice expressing a low level of Igkappa-reactive ligand. <i>Journal of Immunology</i> , 2006 , 176, 939-48	5.3	14
40	Adjuvant-enhanced antibody responses in the absence of toll-like receptor signaling. <i>Science</i> , 2006 , 314, 1936-8	33.3	483
39	Receptor editing in lymphocyte development and central tolerance. <i>Nature Reviews Immunology</i> , 2006 , 6, 728-40	36.5	255
38	A role for nuclear factor kappa B/rel transcription factors in the regulation of the recombinase activator genes. <i>Immunity</i> , 2005 , 22, 519-31	32.3	68
37	An immunoglobulin C kappa-reactive single chain antibody fusion protein induces tolerance through receptor editing in a normal polyclonal immune system. <i>Journal of Experimental Medicine</i> , 2005 , 201, 817-28	16.6	52

36	Peripheral B lymphocyte tolerance. <i>Keio Journal of Medicine</i> , 2004 , 53, 151-8	1.6	1
35	Tolerance-induced receptor selection: scope, sensitivity, locus specificity, and relationship to lymphocyte-positive selection. <i>Immunological Reviews</i> , 2004 , 197, 219-30	11.3	18
34	The scope of receptor editing and its association with autoimmunity. <i>Current Opinion in Immunology</i> , 2004 , 16, 808-14	7.8	36
33	Do B cells take advantage of missing self-recognition?. <i>Current Directions in Autoimmunity</i> , 2003 , 6, 245-64		3
32	Antigen receptor selection by editing or downregulation of V(D)J recombination. <i>Current Opinion in Immunology</i> , 2003 , 15, 182-9	7.8	65
31	Haplotype exclusion and receptor editing: irreconcilable differences?. <i>Seminars in Immunology</i> , 2002 , 14, 191-8; discussion 222-4	10.7	3
30	Contribution of receptor editing to the antibody repertoire. <i>Science</i> , 2001 , 291, 1541-4	33.3	252
29	Role of receptor editing and revision in shaping the B and T lymphocyte repertoire. <i>Life Sciences</i> , 2001 , 69, 1105-13	6.8	31
28	B cell clonal elimination induced by membrane-bound self-antigen may require repeated antigen encounter or cell competition. <i>European Journal of Immunology</i> , 2000 , 30, 689-96	6.1	22
27	Role of B cell antigen receptor in regulation of V(D)J recombination and cell survival. <i>Immunologic Research</i> , 2000 , 21, 259-63	4.3	10
26	T cell-independent rescue of B lymphocytes from peripheral immune tolerance. <i>Science</i> , 2000 , 287, 2501-3	33.3	55
25	A VH11V kappa 9 B cell antigen receptor drives generation of CD5+ B cells both in vivo and in vitro. <i>Journal of Immunology</i> , 2000 , 164, 4586-93	5.3	68
24	Revising B cell receptors. <i>Journal of Experimental Medicine</i> , 2000 , 191, 1813-7	16.6	223
23	Receptor selection in B and T lymphocytes. <i>Annual Review of Immunology</i> , 2000 , 18, 19-51	34.7	170
22	Receptor editing: genetic reprogramming of autoreactive lymphocytes. <i>Cell Biochemistry and Biophysics</i> , 1999 , 31, 81-8	3.2	2
21	V(D)J recombinase induction in splenic B lymphocytes is inhibited by antigen-receptor signalling. <i>Nature</i> , 1998 , 394, 292-5	50.4	105
20	Receptor editing and commitment in B lymphocytes. <i>Current Opinion in Immunology</i> , 1998 , 10, 208-13	7.8	47
19	Developmental regulation of B lymphocyte immune tolerance compartmentalizes clonal selection from receptor selection. <i>Cell</i> , 1998 , 92, 173-82	56.2	204

18	Receptor editing occurs frequently during normal B cell development. <i>Journal of Experimental Medicine</i> , 1998 , 188, 1231-8	16.6	168
17	Efficient peripheral clonal elimination of B lymphocytes in MRL/lpr mice bearing autoantibody transgenes. <i>Journal of Experimental Medicine</i> , 1998 , 188, 909-17	16.6	44
16	Anti-laminin reactivity and glomerular immune deposition by in vitro recombinant antibodies. <i>Autoimmunity</i> , 1997 , 26, 231-43	3	10
15	V(D)J recombination in mature B cells: a mechanism for altering antibody responses. <i>Science</i> , 1997 , 278, 298-301	33.3	222
14	BCR ligation induces receptor editing in IgM+IgD- bone marrow B cells in vitro. <i>Immunity</i> , 1997 , 6, 429-36	2.3	158
13	Receptor editing in a transgenic mouse model: site, efficiency, and role in B cell tolerance and antibody diversification. <i>Immunity</i> , 1997 , 7, 765-75	32.3	246
12	Enforced Bcl-2 expression inhibits antigen-mediated clonal elimination of peripheral B cells in an antigen dose-dependent manner and promotes receptor editing in autoreactive, immature B cells. <i>Journal of Experimental Medicine</i> , 1997 , 186, 1513-22	16.6	118
11	Can receptor editing play an important role in normal B-cell development?. <i>Journal of Autoimmunity</i> , 1996 , 9, 259-61	15.5	9
10	Antigen receptor capacity and the sensitivity of self-tolerance. <i>Trends in Immunology</i> , 1996 , 17, 25-9		69
9	Peripheral deletion of self-reactive B cells. <i>Nature</i> , 1991 , 354, 308-11	50.4	318
8	Vaccine Elicitation of HIV Broadly Neutralizing Antibodies from Engineered B cells		1
7	Structural and functional evaluation of de novo-designed, two-component nanoparticle carriers for HIV Env trimer immunogens		4
6	B cells expressing authentic naive human VRC01-class BCRs can be primed and recruited to germinal centers in multiple independent mouse models		1
5	Commercial Serology Assays Predict Neutralization Activity Against SARS-CoV-2		7
4	Reprogramming the antigen specificity of B cells using genome editing technologies		1
3	In vivo engineered B cells retain memory and secrete high titers of anti-HIV antibodies in mice		1
2	Broadening a SARS-CoV-1 neutralizing antibody for potent SARS-CoV-2 neutralization through directed evolution		3
1	Broadly neutralizing antibodies to SARS-related viruses can be readily induced in rhesus macaques		4

